Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders

ClinicalTrials.gov ID: NCT00846547

Public ClinicalTrials.gov record NCT00846547. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Flexible-Dose Evaluation of the Safety and Tolerability of STX209 for Treatment of Irritability in Subjects With Autism Spectrum Disorders

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study objective is to explore the safety and tolerability of STX209 in subjects with Autism Spectrum Disorders and to obtain preliminary data on several measures of efficacy in treating irritability. We hypothesize that STX209 will be safe and well-tolerated.

Study identification

NCT ID
NCT00846547
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Seaside Therapeutics, Inc.
Industry
Enrollment
32 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
6 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2009
Primary completion
May 31, 2010
Completion
Aug 31, 2010
Last update posted
Jun 13, 2013

2009 – 2010

United States locations

U.S. sites
8
U.S. states
8
U.S. cities
8
Facility City State ZIP Site status
Southwest Autism Research & Resource Center Phoenix Arizona 85006
University of California-Los Angeles Neuropsychiatric Institute Los Angeles California 90024
Yale Child Study Center New Haven Connecticut 06520
Riley Hospital for Children Indianapolis Indiana 46202
University of North Carolina Neurosciences Hospital Chapel Hill North Carolina 27514
Vanderbilt Kennedy Center Nashville Tennessee 37203
Red Oaks Psychiatry Associates, PA Houston Texas 77090
Seattle Children's Hospital Seattle Washington 98101

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00846547, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 13, 2013 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00846547 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →